세계의 줄기세포 어세이 시장 보고서(2025년)
Stem Cell Assay Global Market Report 2025
상품코드 : 1821604
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

줄기세포 어세이 시장의 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 22.2%로 63억 5,000만 달러로 성장할 전망입니다. 예측기간의 주요 동향으로는 3D 세포 배양 모델, 고처리량 스크리닝, 맞춤형 의료, crispr-cas9 및 유전자 편집, 약물의 안전성 및 독성 검사 등이 있습니다.

향후 5년간의 예측 성장률 22.2%는 과거 예측에서 0.2% 감소한 수치입니다. 이러한 성장세 둔화는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 스웨덴과 영국에서 조달하는 유동 세포 계측 키트 및 3D 오가노이드 분석 플랫폼의 비용을 증가시켜 미국 시장을 방해하고 치료법의 검증을 지연시켜 바이오 의약품의 연구 개발 비용을 상승시킬 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

만성질환의 유병률 증가는 미래 줄기세포 어세이 시장의 성장을 이끌 것으로 예측됩니다. 만성질환은 3개월 이상 지속되고 시간이 지남에 따라 악화될 수 있는 질병으로 정의됩니다. 줄기세포는 만성질환을 비롯한 다양한 질병을 치료할 가능성이 있습니다. 줄기세포는 암 등 만성질환의 치료에 도움이 되는 새로운 항체와 특수세포의 개발을 촉진합니다. 예를 들어, 2022년 영국을 거점으로 하는 세계 암 연구기금 인터내셔널의 데이터에 따르면, 영국의 폐암 환자수는 5만700명이었으며, 이는 인구 10만명당 30.1명의 비율에 해당합니다. 같은 해 영국에서는 1만6,855명의 여성이 폐암으로 사망했고, 사망률은 10만명당 17.4명이었습니다. 게다가 2024년 3월 영국 정부의 데이터에 따르면, 2023년까지의 회계연도에 영국에서 186만 2,500명, 즉 인구의 3%가 관상동맥성 심질환(CHD)의 GP 진단을 받은 것이 밝혀졌습니다. 따라서, 만성질환 증가가 줄기세포 어세이 시장의 성장을 가속하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

Stem cells are cells possessing the unique ability to self-renew and differentiate into specialized cell types, serving as the foundational elements for all living organisms. Stem cell assays are specifically designed to explore the growth of human stem cells and examine their biological activities within a controlled environment.

The primary categories within the stem cell assays market include cell viability and toxicity assays, cell apoptosis assays, cell function assays, cell identification assays, isolation and purification assays, and cell differentiation assays, among others. Cell viability and toxicity assays are employed to evaluate the physical and physiological health of cells under various conditions, such as exposure to external stimuli, chemical agents, medicinal treatments, or other factors, aiding in the determination of optimal conditions for cell culture growth. Products associated with these assays include instruments and detection kits utilized in diverse applications like regenerative medicine, therapy development, drug discovery, and clinical research. End users span government research institutes, private research institutes, and industry research.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The stem cell assay market research report is one of a series of new reports from The Business Research Company that provides stem cell assay market statistics, including stem cell assay industry global market size, regional shares, competitors with an stem cell assay market share, detailed stem cell assay market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell assay industry. This stem cell assay market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem cell assay market size has grown exponentially in recent years. It will grow from $2.36 billion in 2024 to $2.84 billion in 2025 at a compound annual growth rate (CAGR) of 20.5%. The growth in the historic period can be attributed to biotechnology advancements, drug discovery and development, regenerative medicine research, disease modeling, public and private investment.

The stem cell assay market size is expected to see exponential growth in the next few years. It will grow to $6.35 billion in 2029 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to personalized medicine and cellTherapy, organoid and tissue engineering, ai and machine learning, emerging technologies, regulatory and ethical considerations.Major trends in the forecast period include 3D cell culture models, high-throughput screening, personalized medicine, crispr-cas9 and genome editing, drug safety and toxicity testing.

The forecast of 22.2% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S.by increasing the cost of flow cytometry kits and 3D organoid assay platforms sourced from Sweden and the UK, thereby slowing therapeutic validation and elevating biopharmaceutical R&D expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of chronic diseases is anticipated to drive the growth of the stem cell assay market in the future. Chronic diseases are defined as ailments or illnesses that persist for three months or longer and may worsen over time. Stem cells possess the potential to treat various diseases, including chronic conditions. They facilitate the development of new antibodies and specialized cells that aid in curing chronic diseases such as cancer. For example, in 2022, data from The World Cancer Research Fund International, a UK-based organization, indicated that there were 50,700 lung cancer cases in the United Kingdom, corresponding to a rate of 30.1 per 100,000 people. That year, 16,855 women died from lung cancer in the UK, resulting in a mortality rate of 17.4 per 100,000. Furthermore, in March 2024, data from The Government of the United Kingdom revealed that in the financial year ending 2023, slightly over 1,862,500 individuals in England, or 3% of the population, received a GP diagnosis of coronary heart disease (CHD). Consequently, the increasing prevalence of chronic diseases is propelling the growth of the stem cell assay market.

The growing healthcare sector is projected to drive the expansion of the stem cell assay market. The healthcare sector, also referred to as the healthcare industry or healthcare system, encompasses a range of organizations, institutions, professionals, and resources committed to delivering medical services, healthcare products, and support aimed at maintaining or enhancing people's health. Within this sector, stem cell assays are utilized for drug discovery and development, toxicity testing, disease modeling, and exploring developmental biology. For example, in 2022, data from the Office for National Statistics, a UK-based national statistics organization focused on epilepsy, indicated that healthcare expenditure in the UK reached approximately $354.88 billion (£283 billion), reflecting a nominal increase of 0.7% compared to 2021 spending. Therefore, the growing healthcare sector is expected to propel the growth of the stem cell assay market in the future.

A key trend gaining traction in the stem cell assay market is product innovation. Major companies in this market are introducing new products to maintain their competitive positions. For example, in May 2022, Beckman Coulter Life Sciences, a US-based healthcare company, introduced the AQUOS STEM System designed to aid in the development of hematopoietic stem cells. This system reduces hands-on time by 95%, minimizes error-prone processes by 87.5%, and shortens turnaround times, running on the AQUIOS CL Flow Cytometer that combines sample preparation and analysis in a compact platform.

Innovative technologies such as the LIVE Cell Death Assay (LCDA) are being developed by major companies in the stem cell assay market to meet the growing demand. LCDA, an automated solution for profiling cell health, death, apoptosis, and necrosis, offers 13 viability and death-related metrics. For instance, in September 2022, Nanolive SA, a Switzerland-based biotechnology company, launched LCDA, which finds applications in drug discovery, enabling the analysis of cell conditions related to health, stress, cell death, and recovery. This method employs machine learning to automatically measure and track cell well-being and the progression of cell death while distinguishing between apoptosis and necrosis.

In July 2022, Fujifilm Cellular Dynamics Inc., a US-based manufacturer of human-induced pluripotent stem cell technologies, entered into a partnership with PhenoVista Biosciences. This collaboration aims to provide drug discovery researchers with services for high content screening imaging using iPSC-derived differentiated cells, contributing to the drug discovery process. PhenoVista Biosciences, a US-based company, specializes in offering imaging-based phenotypic assay services for drug discovery using induced pluripotent stem cells (iPSCs) in screening.

Major companies operating in the stem cell assay market include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories Inc., PerkinElmer Inc., Agilent Technologies Inc., Promega Corporation, Cell Biolabs Inc., Miltenyi Biotec GmbH, STEMCELL Technologies Inc., Bio-Techne Corporation, Charles River Laboratories International Inc., Hemogenix Inc., Lonza Group AG, Takara Bio Inc., Creative Bioarray, AAT Bioquest Inc., BPS Bioscience Inc., Enzo Life Sciences Inc., PromoCell GmbH, Biotium Inc., Geno Technology Inc., Abcam plc, ReachBio Research Labs. Inc., Sartorius AG, Eppendorf AG, Corning Incorporated, MEDIPOST Co. Ltd., Anterogen Co. Ltd., Corestemchemon Inc., Pharmicell Inc., NuVasive Inc., RTI Surgical Holdings Inc., AlloSource LifeSource Services Inc., JCR Pharmaceuticals Co. Ltd.

North America was the largest region in the stem cell assay market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the global stem cell assay industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the stem cell assay market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The stem cell assay market consists of sales of tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, proliferation assays, differentiation assays, function assays, caspase assays and annexin v and cell permeability assays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stem Cell Assay Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stem cell assay market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for stem cell assay ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stem cell assay market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Stem Cell Assay Market Characteristics

3. Stem Cell Assay Market Trends And Strategies

4. Stem Cell Assay Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Stem Cell Assay Growth Analysis And Strategic Analysis Framework

6. Stem Cell Assay Market Segmentation

7. Stem Cell Assay Market Regional And Country Analysis

8. Asia-Pacific Stem Cell Assay Market

9. China Stem Cell Assay Market

10. India Stem Cell Assay Market

11. Japan Stem Cell Assay Market

12. Australia Stem Cell Assay Market

13. Indonesia Stem Cell Assay Market

14. South Korea Stem Cell Assay Market

15. Western Europe Stem Cell Assay Market

16. UK Stem Cell Assay Market

17. Germany Stem Cell Assay Market

18. France Stem Cell Assay Market

19. Italy Stem Cell Assay Market

20. Spain Stem Cell Assay Market

21. Eastern Europe Stem Cell Assay Market

22. Russia Stem Cell Assay Market

23. North America Stem Cell Assay Market

24. USA Stem Cell Assay Market

25. Canada Stem Cell Assay Market

26. South America Stem Cell Assay Market

27. Brazil Stem Cell Assay Market

28. Middle East Stem Cell Assay Market

29. Africa Stem Cell Assay Market

30. Stem Cell Assay Market Competitive Landscape And Company Profiles

31. Stem Cell Assay Market Other Major And Innovative Companies

32. Global Stem Cell Assay Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Stem Cell Assay Market

34. Recent Developments In The Stem Cell Assay Market

35. Stem Cell Assay Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기